<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04547621</url>
  </required_header>
  <id_info>
    <org_study_id>KY2020-791</org_study_id>
    <nct_id>NCT04547621</nct_id>
  </id_info>
  <brief_title>HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM</brief_title>
  <acronym>HSCK-010</acronym>
  <official_title>The Combination of Hypofractionated Stereotactic Radiotherapy and Chemoradiotherapy Using Intensity-Modulated Radiotherapy for Newly Diagnosed Glioblastoma Multiforme: A Prospective, Single-Center, Single-Arm Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety and effectiveness of the combination of 30Gy/5fx HSRT&#xD;
      and 20Gy/10fx IMRT adjuvant therapy. The total biological effective dose (BED) of the PTV is&#xD;
      72 Gy in a ratio of alpha/beta ratio of 3, which equals to the conventional 60Gy/30fx&#xD;
      treatment. This study can provide evidence for future non-inferiority phase III randomized&#xD;
      controlled trials. The abbreviated course of radiotherapy can reduce the treatment time by&#xD;
      half, benefit patients, and utilize the health resource.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From the start of treatment to the date of death or the last follow-up, up to approximately 24 months</time_frame>
    <description>Estimated using the Kaplan-Meier method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From the start of treatment to the date of disease progression or death, up to approximately 24 months</time_frame>
    <description>Estimated using the Kaplan-Meier method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Bimonthly up to intolerance the toxicity or progressive disease (PD), up to approximately 24 months</time_frame>
    <description>ORR is defined as the percentage of subjects with evidence of a confirmed complete response (CR) or partial response (PR) as per Response Assessment in Neuro-Oncology (RANO) prior to progression or any further therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life score (QoL)</measure>
    <time_frame>Bimonthly up to intolerance the toxicity or PD, up to approximately 24 months</time_frame>
    <description>European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) version 3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>Bimonthly up to intolerance the toxicity or PD, up to approximately 24 months</time_frame>
    <description>Mini-Mental State Exam (MMSE, score range 0 to 30) to evaluate the cognitive function. Any score of 24 or more (out of 30) indicates a normal cognition. Below this, scores can indicate severe (≤9 points), moderate (10-18 points) or mild (19-23 points) cognitive impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity rate</measure>
    <time_frame>Bimonthly up to intolerance the toxicity or PD, up to approximately 24 months</time_frame>
    <description>Common Terminology Criteria for Adverse Events (CTCAE) 5.0 to assess the toxicity. Estimated using an exact binomial distribution together with 95% confidence interval.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Glioma, Malignant</condition>
  <arm_group>
    <arm_group_label>HSRT+IMRT+Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intensity-modulated radiotherapy 20Gy/10fx, 5 days a week for 2 weeks.&#xD;
Hypofractionated stereotactic radiotherapy 30Gy/5fx, 5 days a week for 1 week.&#xD;
Temozolomide once daily (75mg/m2/d) orally administered concurrently with radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>Intensity-modulated radiotherapy 20Gy/10fx</description>
    <arm_group_label>HSRT+IMRT+Temozolomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>Hypofractionated Stereotactic Radiotherapy 30Gy/5fx</description>
    <arm_group_label>HSRT+IMRT+Temozolomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Temozolomide 75 mg/m2 concurrently administered with RT.</description>
    <arm_group_label>HSRT+IMRT+Temozolomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-70 years of age;&#xD;
&#xD;
          2. Karnofsky performance status (KPS) ≥ 60 within 14 days prior to registration;&#xD;
&#xD;
          3. Histopathologically proved diagnosis glioblastoma multiforme;&#xD;
&#xD;
          4. Underwent surgery, gross total resection or subtotal resection;&#xD;
&#xD;
          5. Estimated survival of at least 3 months;&#xD;
&#xD;
          6. Hgb &gt; 90/gL; absolute neutrophil count (ANC) &gt; 1.5×109/L, platelets &gt; 80×109/L;&#xD;
             Creatinine &lt; 1.5 times the upper limit of laboratory normal value; Bilirubin &lt; 2 times&#xD;
             the upper limit of laboratory normal value; serum glutamate pyruvate transaminase&#xD;
             (SGPT) or serum glutamate oxaloacetate transaminase (SGOT) &lt; 3 times the upper limit&#xD;
             of laboratory normal value;&#xD;
&#xD;
          7. Signed informed consent form;&#xD;
&#xD;
          8. Agreed to participate in the follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior invasive malignancy unless disease free;&#xD;
&#xD;
          2. Received irradiation or other anti-tumor adjuvant therapies;&#xD;
&#xD;
          3. Brain stem disease or tumor greater than 6 cm in maximum diameter;&#xD;
&#xD;
          4. Prior therapy with an inhibitor of vascular endothelial growth factor (VEGF) or VEGFR;&#xD;
&#xD;
          5. Pregnancy or nursing mothers;&#xD;
&#xD;
          6. Participated in other trials after diagnosis;&#xD;
&#xD;
          7. Influence factors toward oral medications;&#xD;
&#xD;
          8. Patients with CTCAE5.0 grade 3+ bleeding within 4 weeks prior to registration;&#xD;
&#xD;
          9. Suffering from severe cardiovascular disease: myocardial ischemia or myocardial&#xD;
             infarction above grade II, poorly controlled arrhythmias (including men with QTc&#xD;
             interval ≥ 450 ms, women ≥ 470 ms); according to NYHA criteria, grades III to IV&#xD;
             Insufficient function, or cardiac color Doppler ultrasound examination indicates left&#xD;
             ventricular ejection fraction (LVEF) &lt;50%;&#xD;
&#xD;
         10. Long-term unhealed wounds or fractures;&#xD;
&#xD;
         11. History of organ transplantation;&#xD;
&#xD;
         12. Serious diseases that endanger patients' safety or affect patients' completion of&#xD;
             research, according to the researchers' judgment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enmin Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CyberKnife Center, Department of Neurosurgery, Huashan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CyberKnife Center, Department of Neurosurgery, Huashan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96.</citation>
    <PMID>15758009</PMID>
  </reference>
  <reference>
    <citation>Martínez-Carrillo M, Tovar-Martín I, Zurita-Herrera M, Del Moral-Ávila R, Guerrero-Tejada R, Saura-Rojas E, Osorio-Ceballos JL, Arrebola-Moreno JP, Expósito-Hernández J. Salvage radiosurgery for selected patients with recurrent malignant gliomas. Biomed Res Int. 2014;2014:657953. doi: 10.1155/2014/657953. Epub 2014 May 7.</citation>
    <PMID>24895599</PMID>
  </reference>
  <reference>
    <citation>Roa W, Kepka L, Kumar N, Sinaika V, Matiello J, Lomidze D, Hentati D, Guedes de Castro D, Dyttus-Cebulok K, Drodge S, Ghosh S, Jeremić B, Rosenblatt E, Fidarova E. International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme. J Clin Oncol. 2015 Dec 10;33(35):4145-50. doi: 10.1200/JCO.2015.62.6606. Epub 2015 Sep 21.</citation>
    <PMID>26392096</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 7, 2020</study_first_submitted>
  <study_first_submitted_qc>September 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Enmin Wang</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

